Amgen's cholesterol drug evolocumab works in Phase III trial
This article was originally published in Scrip
Executive Summary
Amgen said it experimental drug evolocumab reduced bad cholesterol levels in patients, meeting goals of a late-stage study and bolstering the company's position in a race to bring a new treatment class to market.